Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson to be invalid and entered judgment in favor of Boston Scientific.
As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents"). The patents relate to the use of a drug on a drug-eluting stent.
"We are pleased with the Court's finding that both of these Johnson & Johnson patents are invalid," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific. "Boston Scientific will continue to vigorously defend against any claims of infringement."
Novel cholesterol removal strategy shows potential benefits post-heart attack